Inmune Bio Inc (INMB)

Apr 23, 2025

A stock that deserves closer examination: INmune Bio Inc (INMB) - uspostnews.com

Apr 23, 2025

Apr 23, 2025

(INMB) Technical Data - news.stocktradersdaily.com

Apr 23, 2025

Apr 16, 2025

Inmune Bio Secures Favorable Patentability Opinion for CORDStrom™ - TipRanks

Apr 16, 2025

Apr 16, 2025

INmune Bio secures key patent opinion for CORDStrom platform By Investing.com - Investing.com South Africa

Apr 16, 2025

Apr 16, 2025

INmune Bio Receives Favorable Opinion from USPTO on CORDStrom Patent Application - marketscreener.com

Apr 16, 2025

Apr 16, 2025

INmune Bio Inc. Achieves Key Patent Milestone for CORDStrom™ Cell Therapy Platform - Nasdaq

Apr 16, 2025

Apr 16, 2025

INmune Bio secures key patent opinion for CORDStrom platform - Investing.com

Apr 16, 2025

Apr 16, 2025

Patent Win: INmune Bio's Revolutionary Cell Therapy Secures 20+ Years Protection - Stock Titan

Apr 16, 2025

Apr 16, 2025

INmune Bio Receives Favorable Patentability Opinion for CORDStro - GuruFocus

Apr 16, 2025

Apr 15, 2025

INmune Bio (INMB) Partners with CGT Catapult for Large-Scale Cel - GuruFocus

Apr 15, 2025

Apr 14, 2025

INmune Bio Partners with Cell and Gene Therapy Catapult - MSN

Apr 14, 2025

Apr 14, 2025

INmune Bio (INMB) Partners to Enhance Cell Therapy Production - GuruFocus

Apr 14, 2025

Apr 14, 2025

INmune Bio in pact with Cell and Gene Therapy Catapult (INMB) - Seeking Alpha

Apr 14, 2025

Apr 14, 2025

INmune Bio, CGT Catapult Partner To Scale CORDStrom Manufacturing For Commercial Launch - Nasdaq

Apr 14, 2025

Apr 14, 2025

INmune Bio Collaborating With Cell and Gene Therapy Catapult to Scale Manufacturing - MarketScreener

Apr 14, 2025

Apr 14, 2025

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness - The Manila Times

Apr 14, 2025

Apr 14, 2025

INmune Bio's Game-Changing Partnership Accelerates CORDStrom Production for 4,000 RDEB Patients - Stock Titan

Apr 14, 2025

Apr 09, 2025

Inmune Bio Presents Alzheimer’s Trial Data at Conference - TipRanks

Apr 09, 2025

Apr 07, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average Price Target from Brokerages - Defense World

Apr 07, 2025

Apr 06, 2025

Trend Tracker for (INMB) - news.stocktradersdaily.com

Apr 06, 2025

Apr 04, 2025

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - ADVFN

Apr 04, 2025

Apr 01, 2025

INmune Bio Presents MINDFuL Trial Data At AD/PD 2025 - Nasdaq

Apr 01, 2025

Apr 01, 2025

INmune Bio Presents Baseline Data From MINDFuL Phase II Trial In Early Alzheimer's Disease - Nasdaq

Apr 01, 2025

Apr 01, 2025

INmune Bio presents early Alzheimer’s trial data at AD/PD - Investing.com

Apr 01, 2025

Apr 01, 2025

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study - The Manila Times

Apr 01, 2025

Apr 01, 2025

INmune Bio presents early Alzheimer’s trial data at AD/PD By Investing.com - Investing.com UK

Apr 01, 2025

Mar 31, 2025

Raymond James maintains INmune Bio stock with $23 target By Investing.com - Investing.com Australia

Mar 31, 2025

Mar 31, 2025

Raymond James maintains INmune Bio stock with $23 target - Investing.com India

Mar 31, 2025

Mar 31, 2025

Raymond James Financial Inc. Takes Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World

Mar 31, 2025

Mar 30, 2025

INmune Bio anticipates Alzheimer's trial results within 100 days while advancing therapeutic platforms - MSN

Mar 30, 2025

Mar 29, 2025

INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025

Mar 28, 2025

Scotiabank Remains a Buy on Inmune Bio (INMB) - The Globe and Mail

Mar 28, 2025

Mar 28, 2025

INmune Bio (INMB) Eyes Landmark Developments in 2024 Amid Rising Financial Commitments - GuruFocus

Mar 28, 2025

Mar 28, 2025

Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus - Investing.com Australia

Mar 28, 2025

Mar 28, 2025

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategi - GuruFocus

Mar 28, 2025

Mar 28, 2025

INmune Bio Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 28, 2025

Mar 27, 2025

Earnings call transcript: INmune Bio’s Q4 2024 results highlight innovation focus By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

INmune Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

INmune Bio Inc Reports Q4 EPS of -$0.53 and Revenue of $0.01 Mil - GuruFocus.com

Mar 27, 2025

Mar 27, 2025

INMUNE BIO Earnings Results: $INMB Reports Quarterly Earnings - Nasdaq

Mar 27, 2025

Mar 27, 2025

INmune Bio's Triple Threat: Alzheimer's Trial Fully Enrolled, FDA Designations Secured - Stock Titan

Mar 27, 2025

Mar 27, 2025

(INMB) On The My Stocks Page - news.stocktradersdaily.com

Mar 27, 2025

Mar 26, 2025

What to Expect from INmune Bio's Earnings - Benzinga

Mar 26, 2025

Mar 24, 2025

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 - The Manila Times

Mar 24, 2025

Mar 21, 2025

Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + - Seeking Alpha

Mar 21, 2025

Mar 20, 2025

INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 20, 2025

Mar 18, 2025

INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results (INMB) - Seeking Alpha

Mar 18, 2025